Nvwm LLC Acquires 25,131 Shares of Pfizer Inc. $PFE

Nvwm LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 882.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,980 shares of the biopharmaceutical company’s stock after acquiring an additional 25,131 shares during the period. Nvwm LLC’s holdings in Pfizer were worth $697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of PFE. Horizon Financial Services LLC grew its holdings in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership purchased a new position in shares of Pfizer during the 4th quarter valued at about $28,000. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the 2nd quarter worth approximately $30,000. Finally, Darwin Wealth Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $32,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on PFE shares. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Morgan Stanley set a $27.00 price target on Pfizer and gave the company a “positive” rating in a report on Tuesday, March 17th. UBS Group assumed coverage on Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective on the stock. Finally, Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.19.

Pfizer Price Performance

PFE stock opened at $28.37 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company’s fifty day moving average price is $27.09 and its 200-day moving average price is $25.84. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.75. The company has a market capitalization of $161.29 billion, a PE ratio of 20.86 and a beta of 0.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the company posted $0.63 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.